Tocilizumab in cranial and extracranial giant cell arteritis: a national multicentre study of 471 cases
Year: 2024
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: The spectrum of GCA includes various vascular phenotypes. Tocilizumab (TCZ) is the only biologic therapy currently approved, regardless of phenotype. We aimed to assess the effectiveness of TCZ in various phenotypes. METHODS: This is a multicentre observational study of GCA patients treated with TCZ. They were divided into three phenotypes: (i) cranial (cGCA), (ii) extracranial GCA (ecGCA) and (iii) mixed GCA (mixGCA). Outcomes included clinical remission, EULAR complete remission, relapses, absence of inflammation as shown using imaging techniques, and safety. RESULTS: We studied 471 patients (342 women; mean age 74.0 ± 9.0 years). The phenotypic distribution was: cGCA (n = 217; 46%), mixGCA (174; 37%) and ecGCA (80; 17%). Patients with ecGCA were younger (66.5 ± 10.1 years) than those with cGCA (74.8 ± 8.1) and those with mixGCA (71.4 ± 8.5), and had a longer delayed GCA diagnosis {median [interquartile range (IQR) [6 (1-14)] vs 1 (1-3) vs 2 (1-6) months, respectively}. Systemic manifestations were similar in the three groups, while ischaemic manifestations were more frequent in cGCA. Combined TCZ, in addition to glucocorticoids, was used more frequently in ecGCA (36%). Clinical remission was observed in 51%/43%/47% in cGCA/ecGCA/mixGCA, respectively, after the first month, and in 79%/81%/89% after 24 months. Complete EULAR remission in 35%/27%/28% (after 1 month) and 72%/73%/67% (after 24 months). Absence of inflammation being shown in the imaging techniques was 15%/26% after 12 months, and 22%/7% (ecGCA/mixGCA) (after 24 months). Relevant adverse events were observed in 109 (23.1%) patients. CONCLUSION: TCZ shows rapid and maintained effectiveness in all GCA phenotypes in clinical remission and EULAR complete remission. By contrast, absence of inflammation as shown using imaging techniques was much lower in ecGCA and mixGCA.
Source: Lara D. Veeken
Authors: Ricardo Blanco, Vicente Aldasoro, Olga Maiz, Rafael Melero, Susana Romero-Yuste, Eugenio de Miguel, Iván Ferraz-Amaro, Fernando López-Gutiérrez, Santos Castañeda, Javier Loricera, the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, Javier Narváez, Clara Moriano, Paloma Vela, José L Callejas, Juan Ignacio Villa, Eva Galíndez-Agirregoikoa, Francisca Sivera, Jesús C Fernández-López, Carles Galisteo, Juan C González Nieto, Julio Sánchez-Martín, Juan R de Dios, Esther Fernández, Isabel de la Morena, Patricia Moya, Roser Solans i Laqué, Eva Pérez Pampín, José L Andréu, Marcelino Revenga, Patricia Quiroga-Colina, Eztizen Labrador, Andrea García-Valle, Adela Gallego, Carlota Iñíguez, Noelia Álvarez-Rivas, Cristina Hidalgo, Noemí Garrido-Puñal, Ruth López-González, José A Román-Ivorra, Francisco Miguel Ortiz-Sanjuán, Sara Manrique, Paz Collado, Enrique Raya, Valvanera Pinillos, Francisco Navarro, Alejandro Olivé-Marqués, Francisco J Toyos, María L Marena Rojas, Antoni Juan Más, Beatriz Arca, Carmen Ordás-Calvo, María D Boquet, María L Velloso-Feijoo, Cristina Campos, Íñigo Rúa-Figueroa, Antonio García, Carlos Vázquez, Pau Lluch, Carmen Torres, Cristina Luna, Elena Becerra, Nagore Fernández-Llanio, Arantxa Conesa, Eva Salgado
Institutions: Marqués de Valdecilla University Hospital, Instituto de Investigación Marqués de Valdecilla, Complejo Hospitalario de Navarra, Donostiako Unibertsitate Ospitalea, University Hospital Complex Of Vigo, Complejo Hospitalario de Pontevedra, Hospital Universitario La Paz, Hospital Universitario de Canarias, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Universidad Autónoma de Madrid
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: G6696204527, G8084615122
OpenAlex ID: W4405231840